As a global leader in in vitro diagnostic solutions, AccuBioTech is committed to addressing public health emergencies through innovative technologies. In response to the chikungunya outbreak, we offer rapid testing products to empower healthcare facilities, public health agencies, and communities in combating the epidemic.
According to the World Health Organization (WHO) outbreak report released on May 12, 2025, the French overseas department of La Réunion has reported over 47,500 confirmed cases of chikungunya since August 2024, with 12 associated deaths. Neighboring Mayotte has also detected its first locally transmitted cases, marking the most severe outbreak in the Indian Ocean region in nearly two decades. This underscores the urgent need for rapid diagnosis and containment.
Chikungunya, transmitted by Aedes mosquitoes, causes symptoms such as high fever, severe joint pain, and rash. Severe cases may lead to organ failure or even death. Early diagnosis is critical not only for accelerating patient treatment but also for curbing viral transmission.
As a global leader in in vitro diagnostic solutions, AccuBioTech is committed to addressing public health emergencies through innovative technologies. In response to the chikungunya outbreak, we offer rapid testing products to empower healthcare facilities, public health agencies, and communities in combating the epidemic.
Sample Types: Serum, plasma
Testing Time: Results in 15 minutes
Key Advantages:
Simultaneously detects IgG and IgM antibodies, differentiating acute from past infections.
Sensitivity ≥99.9%, specificity ≥99.9%, aligning with leading international diagnostic standards.
Simple operation requiring no specialized equipment, ideal for primary care and emergency settings.
Sample Types: Whole blood (venipuncture or fingerstick), serum, plasma
Testing Time: 15 minutes (positive results visible in as little as 1 minute)
Key Advantages:
Direct Whole Blood Testing: Fingerstick sampling reduces preprocessing steps, ideal for remote areas and field screenings.
High stability: Room-temperature storage (2-30°C) ensures easy logistics and storage.
Application: Early screening for acute infections
Key Advantages:
Focused IgM detection with 90.3% sensitivity and 100% specificity, ensuring accurate identification of new infections.
Broad sample compatibility for diverse healthcare scenarios.
Rigorous Quality Control: CE-certified and compliant with ISO 13485 standards, guaranteeing reliable results.
Global Impact: Our cassettes have been successfully deployed in tropical regions such as Africa and Southeast Asia, supporting outbreak responses worldwide.
Rapid and Easy: From sample collection to result interpretation in 15 minutes, enabling timely clinical decisions.
AccuBioTech remains dedicated to its mission of “Precision, Reliability, and Affordability,” providing robust support for global public health security. We call on healthcare institutions, disease control centers, and international organizations to join forces in combating chikungunya through advanced diagnostic tools.
AccuBioTech — Help People live healthy lives.
Data Sources: World Health Organization (WHO) "Chikungunya in La Réunion and Mayotte" Outbreak Report (May 12, 2025)